# Xellsmart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xellsmart

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.xellsmart.com
- Total disclosed funding: $115M
- Latest round: Series C (Apr 2, 2026)
- Investors on record: 25

## About

Based in Suzhou, China and founded in 2021, Xellsmart Bio-Pharmaceutical (Suzhou) Co., Ltd., trading as Xellsmart, operates as a stem cell medical services provider that provides stem cell therapy solutions. It has R&D center located in Shanghai and GMP pilot plant and quality control center. It cooperates with Tongji University, Beckley and Peking University, etc. The founder, Xiang  Li, graduated from the School of Life Sciences at Peking University and used to work for Sana Biotechnology. In August 2022, the company has been recognized the top 10 most growing innovative therapy companies. In April 2026, the firm raised CNY 500 million in series C and series C+ funding rounds.

The company adopts reprogramming technology and provides stem cell therapy solutions for patients with Parkinson's disease. Its products include iPS cell line reprogramming, iPSC gene editing platform and pluripotent stem cell induced differentiation platform and the construction of preclinical disease animal models. 

The company generates revenue by providing stem cell therapy solutions.

The company plans to use the latest funding to advance its allogeneic induced pluripotent stem cell derived neural cell programs into confirmatory clinical stages, expand standardized manufacturing and quality control capacity, and support clinical development and commercialization of off the shelf therapies for central nervous system diseases.

## Funding rounds

- Series C, Apr 2, 2026, $72M — Golden China Fund, Hejun Capital, Haitong New Venture Capital, China Reform Holdings, Septwolves Holding, Sincere Capital, Suzhou Angel Investment Guidance Fund, Frees Fund, Boc Private Equity Firm, Shanghai Minhang Financial Investment Development, Yuyao Shunchuang Investment
- Series B, Jun 4, 2025 — Xiamen C&D Group, Sincere Capital, Suzhou Angel Investment Guidance Fund
- Series B, Oct 21, 2024, $14M — Hong Shan, Qiming Venture Partners, Lilly Asia Ventures, Septwolves Holding, Tenykin Capital, Tailong VC, Frees Fund
- Series A, Apr 18, 2023 — Huatai Zijin Investment
- Series A, Nov 8, 2022, $28M — Hong Shan, Qiming Venture Partners, Lilly Asia Ventures, Oriza Holdings, Founder H Fund, Frees Fund, CreditEase Wealth Management, Next Capital, Jinyuan Capital
- Angel, Jun 23, 2021 — TEDA Venture Capital, YuanBio Venture, Frees Fund

## Investors

- TEDA Venture Capital (https://capitalatlas.ai/funds/teda-venture-capital) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Angel, Series A, Series B, Series C
- Hong Shan — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Founder H Fund (https://capitalatlas.ai/funds/founder-h-fund) — Series A
- CreditEase Wealth Management (https://capitalatlas.ai/funds/creditease-wealth-management) — Series A
- Next Capital — Series A
- Jinyuan Capital (https://capitalatlas.ai/funds/jinyuan-capital) — Series A
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series A
- Septwolves Holding (https://capitalatlas.ai/funds/septwolves-holding) — Series B, Series C
- Tenykin Capital (https://capitalatlas.ai/funds/tenykin-capital) — Series B
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series B
- Xiamen C&D Group — Series B
- Sincere Capital (https://capitalatlas.ai/funds/sincere-capital) — Series B, Series C
- Suzhou Angel Investment Guidance Fund (https://capitalatlas.ai/funds/suzhou-angel-investment-guidance-fund) — Series B, Series C
- Golden China Fund (https://capitalatlas.ai/funds/golden-china-fund) — Series C
- Hejun Capital (https://capitalatlas.ai/funds/hejun-capital) — Series C
- Haitong New Venture Capital (https://capitalatlas.ai/funds/haitong-new-venture-capital) — Series C
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series C
- Boc Private Equity Firm (https://capitalatlas.ai/funds/boc-private-equity-firm) — Series C
- Shanghai Minhang Financial Investment Development — Series C
- Yuyao Shunchuang Investment — Series C